Kari Grønås

Director at Ultimovacs

Kari Grønås has served as a Board Member since 2019. Kari Grønås (1964) has broad experience from the pharmaceutical/biotech industry. She has extensive experience in drug development and commercialization within the pharmaceutical industry of new breakthrough products securing regulatory approvals, i.e. Xofigo, Hexvix. Grønås also holds significant leadership and management experience including leadership of cross functional and governance teams from Bayer/Algeta ASA, PhotoCure and Nycomed Imaging/Amersham Health (Now GE Healthcare). Today she is a consultant within the sector and holds board positions in Spago Nanomedical AB, Arxx AS and The Norwegian Lung Cancer Society. Ms Grønås hold s a Cand. Pharm. (M. Sci. Pharm) from the University of Oslo (UIO).

Timeline

  • Director

    Current role